Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861614 · ClinicalTrials.gov registry record · Phase 3
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 988
- Enrollment target
NCT00861614 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 988 participants.
The verdict
NCT00861614, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 988 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone
Interventions
- DRUG Placebo
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 988 participants |
| Start Date | 2009-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00861614
The ClinicalTrials.gov registry entry for NCT00861614 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 988 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00861614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00861614 about?
NCT00861614 is a clinical study titled "Study of Immunotherapy to Treat Advanced Prostate Cancer". The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone
What is the current status of trial NCT00861614?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 988 participants. The study started on 2009-05. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00861614?
The interventions under investigation include: Placebo (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT00861614?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.